Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Mitsubishi Tanabe Taps Moderna’s Nagayama as New EVP Post
Mitsubishi Tanabe Pharma said on May 26 that it has appointed Kazumasa Nagayama, who has led the Japan unit of Moderna, for a newly created post of corporate executive vice president, effective June 1. The corporate executive vice president will…
To read the full story
Related Article
BUSINESS
- Taisho Bags Japan Rights to Kaigene’s FcRn Inhibitor KG006
August 3, 2026
- Datroway Lands EU Approval in 1st-Line TNBC
August 3, 2026
- Chugai Files Enspryng for MOGAD Relapse Prevention in Japan
August 3, 2026
- Takeda CEO Says Orzeyful Could Redefine NT1 Standard of Care
July 31, 2026
- Pfizer Seeks Pediatric Expansion for Hympavzi in Japan
July 31, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…